The United States FDA Awards Orphan Drug Designation (ODD) to NM5072 for Treating Paroxysmal Nocturnal Hemoglobinuria
CLEVELAND, OHIO, UNITED STATES, April 15, 2024 /EINPresswire.com/ -- NovelMed today announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NM5072, an AP blocker anti-Properdin antibody, for the …